




Pertussis Rates, 1997-2002
Rates by Age Group



Pertussis

Pertussis

Pertussis, or whooping cough, is an acute infectious disease caused by the bacterium *Bordetella pertussis*. Outbreaks of pertussis were first described in the 16th century, and the organism was first isolated in 1906.

In the 20th century, pertussis was one of the most common childhood diseases and a major cause of childhood mortality in the United States. Before the availability of pertussis vaccine in the 1940s, more than 200,000 cases of pertussis were reported annually. Since widespread use of the vaccine began, incidence has decreased more than 80% compared with the prevaccine era.

Pertussis remains a major health problem among children in developing countries, with 294,000 deaths resulting from the disease in 2002 (World Health Organization estimate).

Bordetella pertussis

B. pertussis is a small, aerobic gram-negative rod. It is fastidious and requires special media for isolation (see Laboratory Diagnosis).

B. pertussis produces multiple antigenic and biologically active products, including pertussis toxin, filamentous hemagglutinin, agglutinogens, adenylate cyclase, pertactin, and tracheal cytotoxin. These products are responsible for the clinical features of pertussis disease, and an immune response to one or more produces immunity following infection. Immunity following *B. pertussis* infection does not appear to be permanent.

Pathogenesis

Pertussis is primarily a toxin-mediated disease. The bacteria attach to the cilia of the respiratory epithelial cells, produce toxins that paralyze the cilia, and cause inflammation of the respiratory tract, which interferes with the clearing of pulmonary secretions. Pertussis antigens appear to allow the organism to evade host defenses, in that lymphocytosis is promoted but chemotaxis is impaired. Until recently it was thought that *B. pertussis* did not invade the tissues. However, recent studies have shown the bacteria to be present in alveolar macrophages.

Clinical Features

The incubation period of pertussis is commonly 7–10 days, with a range of 4–21 days, and rarely may be as long as 42 days. The clinical course of the illness is divided into three stages.

Pertussis

- Highly contagious respiratory infection caused by *Bordetella pertussis*
- Outbreaks first described in 16th century
- *Bordetella pertussis* isolated in 1906
- Estimated 294,000 deaths worldwide in 2002

Bordetella pertussis

- Fastidious gram-negative bacteria
- Antigenic and biologically active components:
 - pertussis toxin (PT)
 - filamentous hemagglutinin (FHA)
 - agglutinogens
 - adenylate cyclase
 - pertactin
 - tracheal cytotoxin

Pertussis Pathogenesis

- Primarily a toxin-mediated disease
- Bacteria attach to cilia of respiratory epithelial cells
- Inflammation occurs which interferes with clearance of pulmonary secretions
- Pertussis antigens allow evasion of host defenses (lymphocytosis promoted but impaired chemotaxis)

Pertussis Clinical Features

- Incubation period 7-10 days (range 4-21 days)
- Insidious onset, similar to minor upper respiratory infection with nonspecific cough
- Fever usually minimal throughout course of illness

Pertussis Clinical Features

- Catarrhal stage 1-2 weeks
- Paroxysmal cough stage 1-6 weeks
- Convalescence Weeks to months

Pertussis Among Adolescents and Adults

- Disease often milder than in infants and children
- Infection may be asymptomatic, or may present as classic pertussis
- Persons with mild disease may transmit the infection
- Older persons often source of infection for children

Pertussis Complications*

Condition	Percent reported
Pneumonia	5.2
Seizures	0.8
Encephalopathy	0.1
Hospitalization	20
Death	0.2

*Cases reported to CDC 1997-2000 (N=28,187)

The first stage, the catarrhal stage, is characterized by the insidious onset of coryza (runny nose), sneezing, low-grade fever, and a mild, occasional cough, similar to the common cold. The cough gradually becomes more severe, and after 1–2 weeks, the second, or paroxysmal stage, begins. Fever is generally minimal throughout the course of the illness.

It is during the paroxysmal stage that the diagnosis of pertussis is usually suspected. Characteristically, the patient has bursts, or paroxysms, of numerous, rapid coughs, apparently due to difficulty expelling thick mucus from the tracheobronchial tree. At the end of the paroxysm, a long inspiratory effort is usually accompanied by a characteristic high-pitched whoop. During such an attack, the patient may become cyanotic (turn blue). Children and young infants, especially, appear very ill and distressed. Vomiting and exhaustion commonly follow the episode. The person does not appear to be ill between attacks.

Paroxysmal attacks occur more frequently at night, with an average of 15 attacks per 24 hours. During the first 1 or 2 weeks of this stage, the attacks increase in frequency, remain at the same level for 2 to 3 weeks, and then gradually decrease. The paroxysmal stage usually lasts 1 to 6 weeks but may persist for up to 10 weeks. Infants younger than 6 months of age may not have the strength to have a whoop, but they do have paroxysms of coughing.

In the convalescent stage, recovery is gradual. The cough becomes less paroxysmal and disappears in 2 to 3 weeks. However, paroxysms often recur with subsequent respiratory infections for many months after the onset of pertussis.

Adolescents and adults and children partially protected by the vaccine may become infected with *B. pertussis* but may have milder disease than infants and young children. Pertussis infection in these persons may be asymptomatic, or present as illness ranging from a mild cough illness to classic pertussis with persistent cough (i.e., lasting more than 7 days). Inspiratory whoop is not common.

Even though the disease may be milder in older persons, those who are infected may transmit the disease to other susceptible persons, including unimmunized or incompletely immunized infants. Older persons are often found to have the first case in a household with multiple pertussis cases, and are often the source of infection for children.

Complications

The most common complication, and the cause of most pertussis-related deaths, is secondary bacterial pneumonia. Young infants are at highest risk for acquiring pertussis-associated

complications. Data from 1997–2000 indicate that pneumonia occurred in 5.2% of all reported pertussis cases, and among 11.8% of infants younger than 6 months of age.

Neurologic complications such as seizures and encephalopathy (a diffuse disorder of the brain) may occur as a result of hypoxia (reduction of oxygen supply) from coughing, or possibly from toxin. Neurologic complications of pertussis are more common among infants. Other less serious complications of pertussis include otitis media, anorexia, and dehydration. Complications resulting from pressure effects of severe paroxysms include pneumothorax, epistaxis, subdural hematomas, hernias, and rectal prolapse.

In 2004–05 a total of 66 deaths from pertussis were reported to the CDC. Children 3 months of age or younger accounted for 56 (85%) of these deaths.


Adolescents and adults may also develop complications of pertussis, such as difficulty sleeping, urinary incontinence, pneumonia, and rib fracture.

Laboratory Diagnosis

The diagnosis of pertussis is based on a characteristic clinical history (cough for more than 2 weeks with whoop, paroxysms, or posttussive vomiting) as well as a variety of laboratory tests (culture, polymerase chain reaction [PCR], direct fluorescent antibody [DFA] and serology).

Culture is considered the gold standard laboratory test and is the most specific of the laboratory tests for pertussis. However, fastidious growth requirements make *B. pertussis* difficult to culture. The yield of culture can be affected by specimen collection, transportation, and isolation techniques. Specimens from the posterior nasopharynx, not the throat, should be obtained using Dacron® or calcium alginate (not cotton) swabs. Isolation rates are highest during the first 3 to 4 weeks of illness (catarrhal and early paroxysmal stages). Cultures are variably positive (30%–50%) and may take as long as 2 weeks, so results may be too late for clinical usefulness. Cultures are less likely to be positive if performed later in the course of illness (more than 2 weeks after cough onset) or on specimens from persons who have received antibiotics or have been vaccinated. Since adolescents and adults have often been coughing for several weeks before they seek medical attention, it is often too late for culture to be useful.

Because of the increased sensitivity and faster reporting of results of PCR, many laboratories are now using this method exclusively. PCR should be used in addition to, and not as a replacement for culture. No PCR product has been



approved by the Food and Drug Administration (FDA), and there are no standardized protocols, reagents, or reporting formats for pertussis PCR testing. Consequently, PCR assays vary widely among laboratories. Specificity can be poor, with high rates of false-positive results in some laboratories. Like culture, PCR is also affected by specimen collection. An inappropriately obtained nasopharyngeal swab will likely be negative by both culture and PCR. PCR is less affected by prior antibiotic therapy, since the organism does not need to be viable to be positive by PCR. Continued use of culture is essential for confirmation of PCR results.

DFA testing of nasopharyngeal specimens may be useful as a rapid screening test for pertussis. Use of the monoclonal DFA test has improved the specificity, but DFA still has a low sensitivity and should not be relied upon as a criterion for laboratory confirmation.

Serologic testing could be useful for adults and adolescents who present late in the course of their illness, when both culture and PCR are likely to be negative. However, there is no FDA-approved diagnostic test. The currently available serologic tests measure antibodies that could result from either infection or vaccination, so a positive serologic response simply means that the person has been exposed to pertussis by either recent or remote infection or by recent or remote vaccination. Since vaccination can induce both IgM and IgA antibodies (in addition to IgG antibodies), use of such serologic assays cannot differentiate infection from vaccine response. At this time, serologic test results should not be relied upon for case confirmation of pertussis infection.

An elevated white blood cell count with a lymphocytosis is usually present in classical disease of infants. The absolute lymphocyte count often reaches 20,000 or greater. However, there may be no lymphocytosis in some infants and children or in persons with mild or modified cases of pertussis. More information on the laboratory diagnosis of pertussis is available at <http://www.cdc.gov/vaccines/pubs/surv-manual/default.pdf>

Medical Management

The medical management of pertussis cases is primarily supportive, although antibiotics are of some value. Erythromycin is the drug of choice. This therapy eradicates the organism from secretions, thereby decreasing communicability and, if initiated early, may modify the course of the illness.

An antibiotic effective against pertussis (such as azithromycin, erythromycin or trimethoprim-sulfamethoxazole) should be administered to all close contacts of persons with pertussis, regardless of age and vaccination status. Revised treatment and postexposure prophylaxis recommendations

were published in December 2005 (see reference list). All close contacts younger than 7 years of age who have not completed the four-dose primary series should complete the series with the minimal intervals. (see table in Appendix A). Close contacts who are 4–6 years of age and who have not yet received the second booster dose (usually the fifth dose of DTaP) should be vaccinated. The administration of Tdap to persons 10 through 64 years of age who have been exposed to a person with pertussis is not contraindicated, but the efficacy of postexposure use of Tdap is unknown.

Epidemiology

Occurrence

Pertussis occurs worldwide.

Reservoir

Pertussis is a human disease. No animal or insect source or vector is known to exist. Adolescents and adults are an important reservoir for *B. pertussis* and are often the source of infection for infants.

Transmission

Transmission most commonly occurs by the respiratory route through contact with respiratory droplets, or by contact with airborne droplets of respiratory secretions. Transmission occurs less frequently by contact with freshly contaminated articles of an infected person.

Temporal Pattern

Pertussis has no distinct seasonal pattern, but it may increase in the summer and fall.

Communicability

Pertussis is highly communicable, as evidenced by secondary attack rates of 80% among susceptible household contacts. Persons with pertussis are most infectious during the catarrhal period and the first 2 weeks after cough onset (i.e., approximately 21 days).

Secular Trends in the United States

Before the availability of vaccine, pertussis was a common cause of morbidity and mortality among children. During the 6-year period from 1940 through 1945, more than 1 million cases of pertussis were reported, an average of 175,000 cases per year (incidence of approximately 150 cases per 100,000 population).


Pertussis Epidemiology

- **Reservoir** Human
Adolescents and adults
- **Transmission** Respiratory droplets
- **Communicability** Maximum in catarrhal stage
Secondary attack rate up to 80%


Pertussis

7


Pertussis—United States, 1940-2005



Pertussis—United States, 1980-2005



Reported Pertussis by Age Group, 1990-2005



Following introduction of whole-cell pertussis vaccine in the 1940s, pertussis incidence gradually declined, reaching 15,000 reported cases in 1960 (approximately 8 per 100,000 population). By 1970, annual incidence was fewer than 5,000 cases per year, and during 1980–1990, an average of 2,900 cases per year were reported (approximately 1 per 100,000 population).

Pertussis incidence has been gradually increasing since the early 1980s. A total of 25,827 cases was reported in 2004, the largest number since 1959. The reasons for the increase are not clear.

During 2001–2003, the highest average annual pertussis incidence was among infants younger than 1 year of age (55.2 cases per 100,000 population), and particularly among children younger than 6 months of age (98.2 per 100,000 population). In 2002, 24% of all reported cases were in this age group. However, in recent years, adolescents (11–18 years of age) and adults (19 years and older) have accounted for an increasing proportion of cases. During 2001–2003, the annual incidence of pertussis among persons aged 10–19 years increased from 5.5 per 100,000 in 2001, to 6.7 in 2002, and 10.9 in 2003. In 2004 and 2005, approximately 60% of reported cases were among persons 11 years of age and older. Increased recognition and diagnosis of pertussis in older age groups probably contributed to this increase of reported cases among adolescents and adults.

Of the 10,650 children 3 months to 4 years of age with reported pertussis during 1990–1996 and known vaccination status, 54% were not age-appropriately vaccinated with DTaP.

Pertussis Surveillance

Pertussis cases are reported to CDC via two systems. States provide information about cases of pertussis, including demographic information, through the National Electronic Transmittal System for Surveillance. More detailed information is reported to CDC through the Supplementary Pertussis Surveillance System. Although many pertussis cases are not reported, the surveillance system is useful for monitoring epidemiologic trends. For instance, although the highest incidence of pertussis occurs in infancy, the age group at greatest risk for severe illness and complications, in recent years, the surveillance system has reflected an increase in the incidence of pertussis in all age groups, most notably among adolescents and adults.

Guidelines on pertussis surveillance and outbreak control are available at <http://www.cdc.gov/vaccines/pubs/pertussis-guide/guide.htm>.

Case Definition

The current case definition for pertussis was developed and adopted by the Council of State and Territorial Epidemiologists (CSTE) and CDC. It defines a clinical case of pertussis as an acute cough illness lasting at least 2 weeks with either paroxysms of coughing, inspiratory “whoop,” or posttussive vomiting without other apparent cause (as reported by a health professional).

Case Classification

Probable—Meets the clinical case definition, but is not laboratory confirmed and is not epidemiologically linked to a laboratory-confirmed case.

Confirmed—A clinically compatible case that is laboratory confirmed or epidemiologically linked to a laboratory-confirmed case.

The clinical case definition above is appropriate for endemic or sporadic cases. In outbreak settings, including household exposures, a case can be defined as an acute cough illness lasting at least 2 weeks without other symptoms. See the pertussis chapter of the Manual for the Surveillance of Vaccine-Preventable Diseases (available at <http://www.cdc.gov/vaccines/pubs/surv-manual/default.htm>) for more information on case classification.

Pertussis Vaccines

Whole-Cell Pertussis Vaccine

Whole-cell pertussis vaccine is composed of a suspension of formalin-inactivated *B. pertussis* cells. It was developed in the 1930s and used widely in clinical practice by the mid-1940s.

Based on controlled efficacy trials conducted in the 1940s and on subsequent observational efficacy studies, a primary series of four doses of whole-cell DTP vaccine was 70%–90% effective in preventing serious pertussis disease. Protection decreased with time, resulting in little or no protection 5 to 10 years following the last dose. Local reactions such as redness, swelling, and pain at the injection site occurred following up to half of doses of whole-cell DTP vaccines. Fever and other mild systemic events were also common. Concerns about safety led to the development of more purified (acellular) pertussis vaccines that are associated with a lower frequency of adverse reactions. Whole-cell pertussis vaccines are no longer available in the United States but are still used in many other countries.

Whole-Cell Pertussis Vaccine

- Developed in mid-1930s and combined as DTP in mid-1940s
- 70%-90% efficacy after 3 doses
- Protection for 5-10 years
- Local adverse reactions common

Pertussis-containing Vaccines

- **DTaP (pediatric)**
—approved for children 6 weeks through 6 years (to age 7 years)
- **Tdap (adolescent and adult)**
—approved for persons 10 through 18 years (Boostrix) and 11 through 64 years (Adacel)

Composition* of Acellular Pertussis Vaccines

Product	PT	FHA	PERT	FIM
Daptacel	10	5	3	5
Infanrix	25	25	8	--
Tripedia	23	23	--	--
Boostrix	8	8	2.5	--
Adacel	2.5	5	3	5

*mcg per dose

Acellular Pertussis Vaccine

Characteristics

Acellular pertussis vaccines are subunit vaccines that contain purified, inactivated components of *B. pertussis* cells. Several acellular pertussis vaccines have been developed for different age groups; these contain different pertussis components in varying concentrations. Acellular pertussis vaccines are available only as combinations with tetanus and diphtheria toxoids.

Pediatric Formulation (DTaP)

Three pediatric acellular pertussis vaccines are currently available for use in the United States. All three vaccines are combined with diphtheria and tetanus toxoids as DTaP and are approved for children 6 weeks through 6 years of age (to age 7 years). *Infanrix* (GlaxoSmithKline) contains three antigens, mostly pertussis toxin (PT) and FHA. *Tripedia* (sanofi pasteur) contains two components, FHA and PT, in equal amounts. *Daptacel* (sanofi pasteur) contains five components, PT, FHA, pertactin, and fimbriae types 2 and 3. None of the available DTaP vaccines contains thimerosal as a preservative, although *Infanrix* and *Daptacel* contain 2-phenoxyethanol as a preservative. *Tripedia* does not contain a preservative. All three vaccines are supplied in single-dose vials or syringes.

Adolescent and Adult Formulation (Tdap)

Acellular pertussis-containing vaccines were first licensed for adolescents and adults in 2005. Two vaccines are currently available. Both vaccines are combined with tetanus toxoid and a reduced amount of diphtheria toxoid compared with pediatric DTaP (that is, similar quantities of tetanus and diphtheria toxoid to adult formulation Td). *Boostrix* (GlaxoSmithKline) is approved for persons 10 through 18 years of age, and contains three pertussis antigens (PT, FHA, and pertactin) in a reduced quantity compared with the GlaxoSmithKline pediatric formulation. The vaccine contains aluminum hydroxide as an adjuvant and does not contain a preservative. *Adacel* (sanofi pasteur) is approved for persons 11 through 64 years of age. It contains the same five pertussis components as *Daptacel* but with a reduced quantity of PT. *Adacel* contains aluminum phosphate as an adjuvant and does not contain a preservative. Both vaccines are supplied as single-dose vials or syringes.

Immunogenicity and Vaccine Efficacy

DTaP

Since 1991, several studies conducted in Europe and Africa have evaluated the efficacy of DTaP vaccines administered to infants. These studies varied in type and number of vaccines, design, case definition, and laboratory method used to confirm the diagnosis of pertussis, so comparison among studies must be made with caution. Point estimates of vaccine efficacy ranged from 80% to 85% for vaccines currently licensed in the United States. Confidence intervals for vaccine efficacy overlap, suggesting that none of the vaccines is significantly more effective than the others. When studied, the acellular pertussis vaccine was significantly more effective than whole-cell DTP. Mild local and systemic adverse reactions and more serious adverse reactions (such as high fever, persistent crying, hypotonic hyporesponsive episodes, and seizures) occurred less frequently among infants vaccinated with acellular pertussis vaccines than among those vaccinated with whole-cell DTP.

Tdap

Adolescent and adult formulation Tdap vaccines were licensed on the basis of noninferiority of the serologic response to the various components compared with each company's pediatric DTaP formulation (Infanrix and Daptacel) among persons who had received pediatric DTaP or DTP in childhood. For both vaccines, the antibody response to a single dose of Tdap was similar to that following three doses of DTaP in infants. This type of study is known as "bridging." The new vaccines are assumed to have similar clinical efficacy as DTaP vaccine since a similar level of antibody to the components was achieved.

Vaccination Schedule and Use

DTaP

The primary series of DTaP vaccine consists of four doses, the first three doses given at 4- to 8-week intervals (minimum of 4 weeks), beginning at 6 weeks to 2 months of age. The fourth dose is given 6–12 months after the third to maintain adequate immunity for the ensuing preschool years. DTaP should be administered simultaneously with all other indicated vaccines.

The fourth dose of all brands of DTaP is licensed, and recommended by ACIP, to be administered at 15–18 months of age (17–20 months for Daptacel). However, ACIP

DTaP Clinical Trials

<u>Product</u>	<u>Location</u>	<u>VE (95% CI)</u>
Daptacel	Sweden	85% (80-89)
Tripedia	Germany	80% (59-90)
Infanrix	Italy	84% (76-89)

Routine DTaP Primary Vaccination Schedule

<u>Dose</u>	<u>Age</u>	<u>Minimum Interval</u>
Primary 1	2 months	---
Primary 2	4 months	4 weeks
Primary 3	6 months	4 weeks
Primary 4	15-18 months	6 months

Pertussis

DTaP Fourth Dose

- Recommended at 15-18 months*
- May be given earlier if:
 - child is 12 months of age, and
 - 6 months since DTaP3, and
 - unlikely to return at 15-18 months

*17-20 months for Daptacel

School Entry (Fifth) Dose

- Fifth dose recommended when 4th dose given before age 4 years
- *Infanrix* and *Tripedia* licensed for 5th dose after DTaP series

Interchangeability of Different Brands of DTaP Vaccine

- Series should be completed with same brand of vaccine if possible
- Limited data suggest that “mix and match” DTaP schedules do not adversely affect safety and immunogenicity
- Use different brand of DTaP if necessary

Tdap Vaccines

- *Boostrix* (GlaxoSmithKline)
 - approved for persons 10-18 years of age
- *Adacel* (sanofi pasteur)
 - approved for persons 11-64 years of age

recommends that in certain circumstances the fourth dose be given earlier than 15 months of age. The fourth dose of DTaP may be given if the child is at least 12 months of age, and at least 6 months have elapsed since the third dose of pertussis vaccine was given, and, in the opinion of the immunization provider, the child is unlikely to return for an additional visit at 15–18 months of age. All three of these criteria should be met in order to administer the fourth dose of DTaP at 12–14 months of age.

Children who received all four primary doses before the fourth birthday should receive a fifth (booster) dose of DTaP before entering school. This booster dose is not necessary (but may be given) if the fourth dose in the primary series was given on or after the fourth birthday. The booster dose increases antibody levels and may decrease the risk of school-age children transmitting the disease to younger siblings who are not fully vaccinated. *Infanrix* and *Tripedia* are approved for the fifth dose following a series of four doses of DTaP.

For children who started the vaccination series with whole-cell DTP, DTaP should be substituted for any remaining doses of the pertussis series.

ACIP recommends that the series be completed with the same brand of DTaP vaccine if possible. However, limited data suggest that “mix and match” DTaP schedules do not adversely affect safety and immunogenicity. If the vaccine provider do not know or have available the type of DTaP vaccine previously administered to a child, any available DTaP vaccine should be used to continue or complete the vaccination series. Unavailability of the vaccine used for earlier doses is not a reason for missing the opportunity to administer a dose of acellular pertussis vaccine for which the child is eligible.

Interruption of the recommended schedule or delayed doses does not lead to a reduction in the level of immunity reached on completion of the primary series. There is no need to restart a series regardless of the time that has elapsed between doses.

Tdap

Both Tdap vaccines are approved by the Food and Drug Administration for a single (booster) dose for persons who have completed the recommended childhood DTP/DTaP vaccination series. The two vaccines are approved for use in different age groups: *Boostrix* is approved for persons 10–18 years of age; *Adacel* is approved for persons 11–64 years of age.

ACIP recommends that adolescents 11–12 years of age should receive a single dose of Tdap instead of Td.

Adolescents 13–18 years who have not received Tdap should receive a single dose of Tdap as their catch-up booster instead of Td if they have completed the recommended childhood DTaP/DTP vaccination series, and have not yet received a Td booster.

A 5-year interval between Td and Tdap is encouraged to reduce the risk of local and systemic adverse reactions. However, ACIP did not define an absolute minimum interval between Td and Tdap. The interval between Td and Tdap may be shorter than 5 years if protection from pertussis needed. The decision whether to administer Tdap when less than 5 years has elapsed since the last dose of Td should be based on whether the benefit of pertussis immunity outweighs the risk of a local adverse reaction. An interval of less than 5 years can be considered in situations of increased risk of pertussis, such as during a pertussis outbreak, or if protection is needed because of household or other close contact with an infant younger than 12 months of age or a young child who has not been vaccinated against pertussis.

ACIP recommends that adults 19 through 64 years of age receive a single dose of Adacel to replace a single dose of Td for booster immunization against tetanus, diphtheria and pertussis. Adacel may be given at an interval less than 10 years since receipt of the last tetanus toxoid-containing vaccine to protect against pertussis. Special emphasis should be placed on Tdap vaccination of adults who have close contact with infants, such as childcare and healthcare personnel, and parents. Ideally, Tdap should be given at least 1 month before beginning close contact with the infant.

Any woman who might become pregnant is encouraged to receive a single dose of Tdap if she has not already received a dose. Women who have not received Tdap (including women who are breastfeeding) should receive a dose in the immediate postpartum period, before discharge from the hospital or birthing center, if 2 years or more have elapsed since the last Td. Shorter intervals since the last Td can be used if necessary. If Tdap cannot be administered before discharge, it should be given as soon as feasible. The dose of Tdap replaces the next routine dose of Td.

ACIP recommends Td when tetanus and diphtheria protection is required during pregnancy. However, pregnancy is not a contraindication for use of Tdap. A clinician may choose to administer Tdap to a pregnant woman in certain circumstances, such as during a community pertussis outbreak. When Td or Tdap is administered during pregnancy, the second or third trimester is preferred to avoid coincidental association of vaccination and spontaneous termination of

Recommendations for Tdap Vaccination of Adolescents

- Adolescents 11-12 years of age should receive a single dose of Tdap instead of Td*
- Adolescents 13-18 years who have not received Tdap should receive a single dose of Tdap as their catch-up booster instead of Td*

*If the person has completed the recommended childhood DTaP/DTP vaccination series, and has not yet received a Td booster

MMWR 2006;55(RR-3):1-43

Minimum Interval Between Td and Tdap

- A 5-year interval since the last Td dose is encouraged to reduce the chance of a local reaction
- ACIP did not define an absolute minimum interval between Td and Tdap
- Interval between Td and Tdap may be shorter if protection from pertussis needed
- Decision to administer Tdap based on whether the benefit of pertussis immunity outweighs the risk of a local adverse reaction

MMWR 2006;55(RR-3):1-43

Recommendations for Tdap Vaccination of Adults

- Single dose of Adacel to replace a single dose of Td
- May be given at an interval less than 10 years since receipt of last tetanus toxoid-containing vaccine
- Special emphasis on adults with close contact with infants (e.g., childcare and healthcare personnel, and parents)

MMWR 2006;55(RR-17):1-37

Use of Tdap Among Pregnant Women*

- Any woman who might become pregnant is encouraged to receive a single dose of Tdap
- Women who have not received Tdap should receive a dose in the immediate postpartum period
- ACIP recommends Td when tetanus and diphtheria protection is required during pregnancy
- Pregnancy is not a contraindication for Tdap
- Clinician may choose to administer Tdap to a pregnant woman in certain circumstances (such as during a community pertussis outbreak)

*Provisional recommendations approved by ACIP June 28, 2006

Tdap Vaccine and Healthcare Personnel

- Healthcare personnel who work in hospitals or ambulatory care settings and have direct patient contact should receive a single dose of Tdap (Adacel only) as soon as feasible*
- Priority should be given to vaccination of healthcare personnel who have direct contact with infants 12 months of age and younger
- An interval as short as 2 years (or less) from the last dose of Td is recommended for the Tdap dose

*if they have not previously received Tdap
MMWR 2006;55(RR-17):1-37

Tdap For Persons Without A History of DTP or DTaP

- All adolescents and adults should have documentation of having received a series of DTaP, DTP, DT, or Td
- Persons without documentation should receive a series of 3 vaccinations
- Preferred schedule:
 - single dose of Tdap*
 - Td at least 4 weeks after the Tdap dose
 - second dose of Td at least 6 months after the Td dose

*off-label recommendation. MMWR 2006;55(RR-3):1-43

TriHIBit

- DTaP–Hib combination
- Do not use for primary immunization at 2, 4, or 6 months of age
- May be used as the booster dose of the Hib series at 12 months of age or older following any Hib vaccine*

*booster dose should follow prior dose by at least 2 months

a pregnancy, which is more common in the first trimester. Clinicians can choose to administer Tdap instead of Td to pregnant adolescents for routine or “catch-up” vaccination because the incidence of pertussis is high among adolescents. Others for whom Tdap might be considered during pregnancy are pregnant healthcare personnel and child care providers (to prevent transmission to infants younger than 12 months of age and to other vulnerable persons) and pregnant women employed in an institution or living in a community with increased pertussis activity.

Healthcare personnel who work in hospitals or ambulatory care settings and have direct patient contact should receive a single dose of Tdap (Adacel only) as soon as feasible. Priority should be given to vaccination of healthcare personnel who have direct contact with infants 12 months of age and younger. An interval as short as 2 years (or less) from the last dose of Td is recommended for the Tdap dose.

Tdap vaccine may be given at the same visit, or any time before or after any other vaccine.

Immunity following pertussis is not permanent. Persons with a history of pertussis should receive a single dose of Tdap if it is otherwise indicated.

All adolescents and adults should have documentation of having received a primary series of at least three doses of tetanus and diphtheria toxoids during their lifetime. A person without such documentation should receive a series of three doses of tetanus- and diphtheria-containing vaccine. One of these doses, preferably the first, should be Tdap if the person is at least 10 years of age (the minimum age approved for one of the two available Tdap products). The remaining two doses should be adult formulation Td.

No pertussis vaccine is approved for children 7–9 years of age or for persons older than 64 years. ACIP does not recommend the use of Tdap in persons in these age groups.

Combination Vaccines Containing DTaP

TriHIBit

One combination DTaP-Hib (*Haemophilus influenzae* type b) vaccine is currently available in the United States (TriHIBit, sanofi pasteur). The vaccines are provided in separate vials, and the DTaP component (Tripedia) is used to reconstitute the Hib component (ActHIB). No other brand of DTaP and Hib vaccine may be used to produce this combination (e.g., Infanrix must not be substituted for Tripedia). In addition, when supplied as TriHIBit, the DTaP

and Hib components have a single lot number. Providers should generally use only the DTaP and Hib supplied together as TriHIBit. However, it is acceptable to combine Tripedia and ActHIB that have been supplied separately (i.e., not packaged as TriHIBit). In this situation, the lot numbers of both vaccines should be recorded in the child's chart.

Because of evidence of reduced immunogenicity of the Hib component when used as a combination, TriHIBit is not approved by the Food and Drug Administration for use as the primary series at 2, 4, or 6 months of age. It is approved only for the fourth dose of the DTaP and Hib series. If TriHIBit is administered as one or more doses of the primary series at 2, 4, or 6 months of age, the Hib doses should not be counted, and the child should be revaccinated as age-appropriate for Hib. The DTaP doses may be counted as valid and do not need to be repeated.

Although TriHIBit cannot be used in the primary series at 2, 4, or 6 months of age, it may be used as the booster (final) dose following a series of single-antigen Hib vaccine or combination hepatitis B–Hib vaccine (Comvax). TriHIBit can be used if the child is 12 months of age or older, has received at least one prior dose of Hib vaccine 2 or more months earlier, and TriHIBit will be the last dose in the Hib series. For example, TriHIBit can be used for the booster dose at 12–15 months of age in a child who has received Comvax or PedvaxHib at 2 and 4 months of age, or three prior doses of HibTiter or ActHib. TriHIBit can also be used at 15–59 months of age in a child who has received at least one prior dose of any Hib-containing vaccine. TriHIBit should not be used if the child has received no prior Hib doses.

Pediarix

In 2002, the FDA approved Pediarix (GlaxoSmithKline), the first pentavalent (5 component) combination vaccine licensed in the United States. Pediarix contains DTaP (Infanrix), hepatitis B (Engerix-B), and inactivated polio vaccines. In prelicensure studies, the proportion of children who developed a protective level of antibody and the titer of antibody were at least as high when the vaccine antigens were given together as Pediarix as when children received separate vaccines.

The minimum age for the first dose of Pediarix is 6 weeks, so it cannot be used for the birth dose of the hepatitis B series. Pediarix is approved for the first three doses of the DTaP and inactivated polio vaccine (IPV) series, which are usually given at about 2, 4, and 6 months of age; it is not approved for fourth or fifth (booster) doses of the DTaP or IPV series. However, Pediarix is approved for use through

Pediarix

- DTaP–Hep B–IPV combination
- Minimum age 6 weeks
- Approved for 3 doses at 2, 4 and 6 months
- Not approved for booster doses
- Licensed for children 6 weeks through 6 years of age

Pediarix

- May be used interchangeably with other pertussis-containing vaccines if necessary
- Can be given at 2, 4, and 6 months to infants who received a birth dose of hepatitis B vaccine (total of 4 doses)
- May be used in infants whose mothers are HBsAg positive or status is not known*

*off-label recommendation

Pertussis Vaccine Use in Children with Underlying Neurologic Disorders

Underlying Condition	Recommendation
Prior seizure	Delay and assess*
Suspected neurologic disorder	Delay and assess*
Neurologic event between doses	Delay and assess*
Stable/resolved neurologic condition	Vaccinate

*vaccinate after treatment initiated and condition stabilized

Pertussis Vaccination of Children Who Have Recovered From Pertussis

- If documented disease, do not need additional doses of pediatric pertussis vaccine*
- Satisfactory documentation of disease:
 - recovery of *B. pertussis* on culture, or
 - typical symptoms and clinical course when epidemiologically linked to a culture-confirmed case

*Tdap is recommended when the child is age eligible

6 years of age. A child who is behind schedule can receive Pediarix as long as it is given for doses 1, 2, or 3 of the series, and the child is younger than 7 years of age.

A dose of Pediarix inadvertently administered as the fourth or fifth dose of the DTaP or IPV series does not need to be repeated.

Pediarix may be used interchangeably with other pertussis-containing vaccines if necessary (although ACIP prefers the use of the same brand of DTaP for all doses of the series, if possible). It can be given at 2, 4, and 6 months to infants who received a birth dose of hepatitis B vaccine (total of four doses of hepatitis B vaccine). Although not labeled for this indication by FDA, Pediarix may be used in infants whose mothers are HBsAg positive or whose HBsAg status is not known.

Other DTaP Issues

In certain circumstances, vaccination with DTaP vaccine should be delayed until a child with a known or suspected neurologic condition has been evaluated, treatment initiated, and the condition stabilized. These conditions include the presence of an evolving neurologic disorder (e.g., uncontrolled epilepsy, infantile spasms, and progressive encephalopathy), a history of seizures that has not been evaluated, or a neurologic event that occurs between doses of pertussis vaccine.

A family history of seizures or other neurologic diseases, or stable or resolved neurologic conditions (e.g., controlled idiopathic epilepsy, cerebral palsy, developmental delay) are not contraindications to pertussis vaccination. Acetaminophen or ibuprofen may be administered to children with such histories or conditions at the time of DTaP vaccination and for 24 hours thereafter to reduce the possibility of postvaccination fever, which could cause a febrile seizure.

Reducing the dose of whole-cell DTP or DTaP vaccine or giving the full dose in multiple smaller doses may result in an altered immune response and inadequate protection. Furthermore, there is no evidence that the chance of a significant vaccine reaction is likely to be reduced by this practice. The use of multiple reduced doses that together equal a full immunizing dose, or the use of smaller, divided doses is not endorsed or recommended. Any vaccination using less than the standard dose should not be counted, and the person should be revaccinated according to age.

Children who have recovered from documented pertussis do not need additional doses of pediatric pertussis vaccine. However, Tdap vaccine is recommended when the child

becomes age eligible. Satisfactory documentation includes recovery of *B. pertussis* on culture or typical symptoms and clinical course when these are epidemiologically linked to a culture-confirmed case, as may occur during outbreaks. When such confirmation of diagnosis is lacking, vaccination should be completed because cough illness may be caused by other *Bordetella* species, other bacteria, or certain viruses.

Adverse Reactions Following Vaccination

DTaP

As with all injected vaccines, administration of DTaP may cause local reactions, such as pain, redness, or swelling. Local reactions have been reported in 20%–40% of children after the first three doses. Local reactions appear to be more frequent after the fourth and/or fifth doses. Mild systemic reactions such as drowsiness, fretfulness, and low-grade fever may also occur. Temperature of 101°F or higher is reported in 3%–5% of DTaP recipients. These reactions are self-limited and can be managed with symptomatic treatment with acetaminophen or ibuprofen. Moderate or severe systemic reactions (such as fever [105°F or higher], febrile seizures, persistent crying lasting 3 hours or longer, and hypotonic hyporesponsive episodes) have been reported after administration of DTaP but occur less frequently than among children who received whole-cell DTP. Rates of these less common reactions vary by symptom and vaccine but generally occur in fewer than 1 in 10,000 doses. See the pertussis chapter in the textbook *Vaccines* (Plotkin and Orenstein, eds., 2003) for a comprehensive review of DTaP adverse event data.

Information on adverse reactions following a full series of DTaP is also limited. Available data suggest a substantial increase in the frequency and magnitude of local reactions after the fourth and fifth doses. For example, swelling at the site of injection occurred in 2% of patients after the first dose of Tripedia, and in 29% following the fourth dose. Increases in the frequency of fever after the fourth dose have also been reported, although the increased frequencies of other systemic reactions (e.g., fretfulness, drowsiness, or decreased appetite) have not been observed. Further details on this issue can be found in a supplemental ACIP statement published in 2000 (MMWR 2000;49(No RR-13):1–8).

Swelling involving the entire thigh or upper arm has been reported after booster doses of certain acellular pertussis vaccines. The limb swelling may be accompanied by erythema, pain and fever. Although the swelling may interfere with walking, most children have no limitation of activity. The pathogenesis and frequency of substantial local reactions and limb swelling are not known, but these conditions appear to be self-limited and resolve without sequelae.

DTaP Adverse Reactions

- Local reactions (pain, redness, swelling) 20%-40%
- Temp of 101°F or higher 3%-5%
- More severe adverse reactions not common
- Local reactions more common following 4th and 5th doses

Adverse Reactions Following the 4th and 5th DTaP Dose

- Local adverse reactions and fever increased with 4th and 5th doses of DTaP
- Reports of swelling of entire limb
- Extensive swelling after 4th dose NOT a contraindication to 5th dose

Tdap Adverse Reactions

- Local reactions (pain, redness, swelling) 21%-66%
- Temp of 100.4°F or higher 1.4%
- Adverse reactions occur at approximately the same rate as Td alone (without acellular pertussis vaccine)

DTaP Contraindications

- Severe allergic reaction to vaccine component or following a prior dose
- Encephalopathy not due to another identifiable cause occurring within 7 days after vaccination

DTaP Precautions*

- Moderate or severe acute illness
- Temperature 105°F (40.5°C) or higher within 48 hours with no other identifiable cause
- Collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours
- Persistent, inconsolable crying lasting 3 hours or longer, occurring within 48 hours
- Convulsions with or without fever occurring within 3 days

*may consider use in outbreaks

ACIP recommends that a fifth dose of DTaP be administered before a child enters school. It is not known whether children who experience entire limb swelling after a fourth dose of DTaP are at increased risk for this reaction after the fifth dose. Because of the importance of this dose in protecting a child during school years, ACIP recommends that a history of extensive swelling after the fourth dose should not be considered a contraindication to receipt of a fifth dose at school entry. Parents should be informed of the increase in reactogenicity that has been reported following the fourth and fifth doses of DTaP.

Tdap

The safety of Tdap vaccines was evaluated as part of prelicensure studies. The most common adverse reaction following both brands of Tdap vaccine is a local reaction, such as pain (66%), redness (25%) or swelling (21%) at the site of injection. Temperature of 100.4°F or higher was reported by 1.4% of Tdap recipients and 1.1% of Td recipients. Tdap recipients also reported a variety of nonspecific systemic events, such as headache, fatigue and gastrointestinal symptoms. Local reactions, fever, and nonspecific systemic symptoms occurred at approximately the same rate in recipients of Tdap and the comparison group that received Td without acellular pertussis vaccine. No serious adverse events have been attributed to Tdap.

Contraindications and Precautions to Vaccination

DTaP

Contraindications to further vaccination with DTaP are a severe allergic reaction to a vaccine component or following prior dose of vaccine, and encephalopathy not due to another identifiable cause occurring within 7 days after vaccination.

Moderate or severe acute illness is a precaution to vaccination. Children with mild illness, such as otitis media or upper respiratory infection, should be vaccinated. Children for whom vaccination is deferred because of moderate or severe acute illness should be vaccinated when their condition improves.

Certain infrequent adverse reactions following DTaP vaccination are considered to be precautions for subsequent doses of pertussis vaccine. These adverse reactions are a temperature of 105°F (40.5°C) or higher within 48 hours that is not due

to another identifiable cause; collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours; persistent, inconsolable crying lasting 3 hours or longer, occurring within 48 hours; and convulsions with or without fever occurring within 3 days.

There are circumstances (e.g., during a communitywide outbreak of pertussis) in which the benefit of vaccination outweighs the risk, even if one of the four precautionary adverse reactions occurred following a prior dose. In these circumstances, one or more additional doses of pertussis vaccine should be considered. DTaP should be used in these circumstances.

Tdap

Tdap is contraindicated for persons with a history of a severe allergic reaction to a vaccine component or following a prior dose of vaccine. Tdap is also contraindicated for persons with a history of encephalopathy not due to another identifiable cause occurring within 7 days after administration of a pertussis-containing vaccine.

Precautions to Tdap include a history of Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine and a progressive neurologic disorder (such as uncontrolled epilepsy or progressive encephalopathy) until the condition has stabilized. Persons with a history of a severe local reaction (Arthus reaction) following a prior dose of a tetanus and/or diphtheria toxoid-containing vaccine should generally not receive Tdap or Td vaccination until at least 10 years have elapsed after the last Td-containing vaccine. Moderate or severe acute illness is a precaution to vaccination. Persons for whom vaccination is deferred because of moderate or severe acute illness should be vaccinated when their condition improves.

As noted above, certain conditions following DTaP vaccine, such as temperature of 105°F or higher, collapse or shock-like state, persistent crying, or convulsions with or without fever are a precaution to subsequent doses of DTaP. However, occurrence of one of these adverse reactions following DTaP vaccine in childhood is not a contraindication or precaution to administration of Tdap to an adolescent or adult. A history of extensive limb swelling following DTaP is not a contraindication to Tdap vaccination. A stable neurologic disorder (such as controlled seizures or cerebral palsy), pregnancy, breastfeeding, and immunosuppression are not contraindications or precautions to administration of Tdap.

Tdap Contraindications

- Severe allergic reaction to vaccine component or following a prior dose
- Encephalopathy not due to another identifiable cause occurring within 7 days after vaccination with a pertussis-containing vaccine

Tdap Precautions

- History of Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine
- Progressive neurologic disorder until the condition has stabilized
- History of a severe local reaction (Arthus reaction) following a prior dose of a tetanus and/or diphtheria toxoid-containing vaccine
- Moderate or severe acute illness

Pertussis-Containing Vaccines Storage and Handling

- Stored at 35°–46°F (2°–8°C) at all times
- Must never be frozen
- Vaccine exposed to freezing temperature must not be administered and should be discarded
- Should not be used after the expiration date printed on the box or label

Vaccine Storage and Handling

DTaP, Td and Tdap vaccines should be stored at 35°–46°F (2°–8°C) at all times. The vaccines must never be frozen. Vaccine exposed to freezing temperature must not be administered and should be discarded. DTaP, Td and Tdap should not be used after the expiration date printed on the box or label.

Selected References

American Academy of Pediatrics. Pertussis. In: Pickering L, Baker CJ, Long SS, McMillan JA, eds *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006:498–520.

CDC. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46(No. RR-7):1–25.

CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. 2005 CDC Guidelines. *MMWR* 2005;54(No. RR-14):1–16.

CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;55(No. RR-3):1–43.

CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;55(No. RR-17):1–33.

CDC. Pertussis—United States, 2001–2003. *MMWR* 2005;54:1283–6.

Cherry JD, The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of *Bordetella pertussis* infection. *Pediatrics* 2005;115:1422–7.

Edwards K, Decker M. Pertussis vaccine. In: Plotkin SA, Orenstein WA, eds. *Vaccines*. 4th edition. Philadelphia: Saunders; 2003:471–528.

Greenberg DP. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. *Pediatr Infect Dis J* 2005;24:721–8.

Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. *N Engl J Med* 2005;353:1555–63.

Woo EJ, Burwen DR, Gatumu SNM, et al. Extensive limb swelling after immunization: Reports to the Vaccine Adverse Event Reporting System. *Clin Infect Dis* 2003;37:351–8.

Pertussis

7